EGFRi
2 abstracts
Abstract
Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort.Org: Department of Gastrointestinal Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, Guardant Health, Redwood City, CA, Guardant Health, Inc., Redwood City, CA,
Abstract
CfDNA NGS detection of fusions acquired as mechanisms of resistance in the post-EGFR setting across multiple solid tumors.Org: Guardant Health Inc., Palo Alto University, CanSino Biologics, Guardant Health, Inc., Redwood City, CA,